Case histories / Astex Pharmaceuticals

Astex Pharmaceuticals

Astex Pharmaceuticals

Specialising in the discovery and development of small-molecule drugs for oncology and central nervous system disorders.

Niche provided Astex with expert regulatory writing across their oncology pipeline, delivering clinical protocols, study reports and safety narratives largely autonomously and to an exceptionally high standard.

01 Summary

Services NST provided to Astex Pharmaceuticals included medical writing for:

  • Clinical study protocol
  • Protocol amendment
  • Patient adverse event narratives
  • Abbreviated clinical study report.
02 Project background

Astex Pharmaceuticals, founded in 1999 in Cambridge, UK, specialises in the discovery and development of small-molecule drugs for oncology and central nervous system (CNS) disorders. A pioneer in fragment-based drug discovery (FBDD), Astex employs its proprietary Pyramid™ platform to develop innovative therapies targeting challenging or “intractable” diseases. This approach uses small molecular fragments to design drugs with improved properties, aiming to enhance efficacy and reduce drug development attrition rates.

The company has developed a strong pipeline of proprietary and partnered products. Some notable drugs include Guadecitabine, a DNMT inhibitor for hematologic malignancies, and ASTX660, a dual IAP antagonist for solid tumors and lymphomas. Additionally, Astex collaborates with leading pharmaceutical companies, including Novartis (Kisqali®) and Janssen (Balversa®), to advance its compounds to mark

03 Delivery

An important part of Astex’s portfolio is the development of hypomethylating agents for treatment of various diseases, including myelodysplastic syndromes and acute myeloid leukemia. NST was a drug development partner on Astex’s business-critical regulatory writing projects. Projects included clinical protocols, protocol amendments, clinical study reports and safety narratives. The NST team generated high-quality deliverables, largely autonomously, while simplifying complex concepts, drawing on their vast regulatory expertise. NST’s involvement provided valuable writing capacity when Astex’s in-house teams were fully occupied, enabling greater operational efficiency. NST endeavours made an invaluable contribution to Astex’s clinical pipeline.

 

“

The NST teams we worked with delivered high-quality work, including clinical protocols, clinical study report and narrative writing along with performing Quality Reviews of our documents, allowing us to overcome our regulatory hurdles without losing pace on other projects. Importantly, their unique approach to preparing these documents generated outstanding products with only reasonable input from us and minimal revisions – a welcome contrast to other similar firms we had worked with in the past.

Tony WomackAstex Pharmaceuticals ★★★★★

Facing a similar challenge?

Tell us where your programme is. We will show you how we can help.

© 2025 Niche.org.uk     All rights reserved

HomePrivacy policy Corporate Social Responsibility